Abstract
The combination of radiation and chemotherapy, based on a demonstrated preclinical rationale, has involved in the last decades the use of cytotoxic agents as radiosensitizers. Classic chemotherapeutic agents, such as 5-fluouracil and cisplatin, and more recently gemcitabine and taxanes, have been employed in different sequences with radiation therapy, even though the optimal combinations and scheduling are still in evolution. During recent years, due to the highly improved molecular understanding of intrinsic radioresistance and the profiling of cellular response to irradiation, a big effort exists in basic and translational research to identify novel treatment modalities combining radiation therapy with molecules that target very specific molecular pathways.
Keywords: Radiochemotherapy biological rationale, radiation sensitizers, 5-Fluouracil, Platinum, gemcitabine, taxol, epidermal growth factor inhibitors, epigenetic gene expression modulators
Current Drug Therapy
Title: The Association of Chemotherapy and Radiotherapy: Biological Rationale
Volume: 5 Issue: 3
Author(s): Donatella Tirindelli Danesi
Affiliation:
Keywords: Radiochemotherapy biological rationale, radiation sensitizers, 5-Fluouracil, Platinum, gemcitabine, taxol, epidermal growth factor inhibitors, epigenetic gene expression modulators
Abstract: The combination of radiation and chemotherapy, based on a demonstrated preclinical rationale, has involved in the last decades the use of cytotoxic agents as radiosensitizers. Classic chemotherapeutic agents, such as 5-fluouracil and cisplatin, and more recently gemcitabine and taxanes, have been employed in different sequences with radiation therapy, even though the optimal combinations and scheduling are still in evolution. During recent years, due to the highly improved molecular understanding of intrinsic radioresistance and the profiling of cellular response to irradiation, a big effort exists in basic and translational research to identify novel treatment modalities combining radiation therapy with molecules that target very specific molecular pathways.
Export Options
About this article
Cite this article as:
Tirindelli Danesi Donatella, The Association of Chemotherapy and Radiotherapy: Biological Rationale, Current Drug Therapy 2010; 5 (3) . https://dx.doi.org/10.2174/157488510791561101
DOI https://dx.doi.org/10.2174/157488510791561101 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Salidroside - Can it be a Multifunctional Drug?
Current Drug Metabolism Synthetic Src-Kinase Domain Inhibitors and Their Structural Requirements
Anti-Cancer Agents in Medicinal Chemistry Natural Products Targeting Autophagy via the PI3K/Akt/mTOR Pathway as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design The Critical Role of Vascular Endothelial Growth Factor in Tumor Angiogenesis
Current Cancer Drug Targets Inducible Nitric Oxide Synthase-Vascular Endothelial Growth Factor Axis: A Potential Target to Inhibit Tumor Angiogenesis by Dietary Agents
Current Cancer Drug Targets Combined Transarterial Chemoembolization with Microwave Ablation <i>versus</i> Microwave Alone for Treatment of Medium Sized Hepatocellular Carcinoma
Current Cancer Drug Targets Prospects for Plant-Derived Chemopreventive Agents Exhibiting Multiple Mechanisms of Action
Current Medicinal Chemistry - Anti-Cancer Agents Purinergic Receptors and Pain
Current Pharmaceutical Design Preparation, Characterization, Toxicity and Pharmacodynamics of the Inclusion Complex of Brucea javanica Oil with β-cyclodextrin Polymers
Current Pharmaceutical Biotechnology Cellular Functions of RNA-Binding Motif Protein 3 (RBM3): Clues in Hypothermia, Cancer Biology and Apoptosis
Protein & Peptide Letters Honey, Health and Longevity
Current Aging Science PD1/PD-L1 Axis in Uro-oncology
Current Drug Targets Drug Acyl Glucuronides: Reactivity and Analytical Implication
Current Pharmaceutical Analysis Chemoresistance in High-Grade Gliomas: Relevance of Adenosine Signalling in Stem-Like Cells of Glioblastoma Multiforme
Current Drug Targets An Overview on Fibroblast Growth Factors: Structural, Functional and Therapeutic Implications
Current Proteomics Molecular Biomarkers for Lung Adenocarcinoma: A Short Review
Current Cancer Therapy Reviews Micro-RNA in Disease and Gene Therapy
Current Drug Discovery Technologies Identification of Potential Mps1 Inhibitors Through Multiple Pharmacophore- based Virtual Screening and Molecular Docking
Letters in Drug Design & Discovery Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery